115 related articles for article (PubMed ID: 36102441)
1. IMMUNOEXPRESSION OF DEK AND PHOSPHO-P38 PROTEINS IN RECTAL CANCER BEFORE CHEMORADIATION THERAPY.
Tadokoro RB; Cardili L; Artigiani Neto R; Paiotti APR; Oshima CTF; Forones NM
Arq Gastroenterol; 2022; 59(3):414-420. PubMed ID: 36102441
[TBL] [Abstract][Full Text] [Related]
2. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract][Full Text] [Related]
3. High expression of DEK predicts poor prognosis of gastric adenocarcinoma.
Piao J; Shang Y; Liu S; Piao Y; Cui X; Li Y; Lin Z
Diagn Pathol; 2014 Mar; 9():67. PubMed ID: 24650035
[TBL] [Abstract][Full Text] [Related]
4. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
5. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
6. High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
Lee SY; Jung W; Lee J; Kim A; Kim HK; Kim BH
Histol Histopathol; 2019 Nov; 34(11):1279-1288. PubMed ID: 31066459
[TBL] [Abstract][Full Text] [Related]
7. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.
Lin L; Piao J; Gao W; Piao Y; Jin G; Ma Y; Li J; Lin Z
BMC Cancer; 2013 Jul; 13():366. PubMed ID: 23902796
[TBL] [Abstract][Full Text] [Related]
8. High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer.
Wang X; Lin L; Ren X; Lin Z; Li Z; Li C; Jin T
Int J Clin Exp Pathol; 2014; 7(8):5016-23. PubMed ID: 25197373
[TBL] [Abstract][Full Text] [Related]
9. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
10. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.
Datta A; Adelson ME; Mogilevkin Y; Mordechai E; Sidi AA; Trama JP
BMC Cancer; 2011 Jun; 11():234. PubMed ID: 21663673
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer.
Lin L; Piao J; Ma Y; Jin T; Quan C; Kong J; Li Y; Lin Z
PLoS One; 2014; 9(10):e111260. PubMed ID: 25340858
[TBL] [Abstract][Full Text] [Related]
12. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma.
Yi HC; Liu YL; You P; Pan JS; Zhou JY; Liu ZJ; Zhang ZY
Mol Med Rep; 2015 Feb; 11(2):1318-23. PubMed ID: 25351213
[TBL] [Abstract][Full Text] [Related]
14. DEK Is a Potential Biomarker Associated with Malignant Phenotype in Gastric Cancer Tissues and Plasma.
Lee KF; Tsai MM; Tsai CY; Huang CG; Ou YH; Hsieh CC; Hsieh HL; Wang CS; Lin KH
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766266
[TBL] [Abstract][Full Text] [Related]
15. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
[TBL] [Abstract][Full Text] [Related]
16. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract][Full Text] [Related]
17. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma.
Luna-Perez P; Arriola EL; Cuadra Y; Alvarado I; Quintero A
Ann Surg Oncol; 1998; 5(3):203-8. PubMed ID: 9607618
[TBL] [Abstract][Full Text] [Related]
18. DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.
Wang J; Sun L; Yang M; Luo W; Gao Y; Liu Z; Qiu X; Wang E
J Histochem Cytochem; 2013 Jul; 61(7):510-21. PubMed ID: 23571382
[TBL] [Abstract][Full Text] [Related]
19. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
Wang DM; Liu L; Fan L; Zou ZJ; Zhang LN; Yang S; Li JY; Xu W
Cancer Biol Ther; 2012 Dec; 13(14):1522-8. PubMed ID: 23052131
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA SOX2OT maintains the stemness of pancreatic cancer cells by regulating DEK via interacting with miR-200a/141.
Liu CS; Zhou Q; Zhang YD; Fu Y
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2368-2379. PubMed ID: 32196588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
